| Name | Title | Contact Details |
|---|
Human Care HC Sweden AB is a Austin, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
EōS Fitness is the better gym at the better price. Achieve your fitness goals with group classes, tons of equipment, great amenities, personal training and so much more!
The only independent, free standing, non-profit home health care and hospice agency serving the South Shore, NVNA and Hospice provides care to over 27 communities from Milton to Plymouth. Ten-time winner of the national HomeCare Elite Top Agency award, Top 100 the last two years, NVNA and Hospice offers the full continuum of care from certified and private pay home care, to palliative and hospice care. Non-profit hospice residence, the Pat Roche Hospice Home, offers residential hospice care. Specialty services in Alzheimer`s, Diabetes, CHF, Chronic Disease Self Management, Wound Care, and Falls Prevention. Educational programs, free health screenings, and caregiver support groups also offered.
We are a non-profit, Michigan-based company and a subsidiary of the Henry Ford Health System, one of the nation`s leading health care systems. We provide health plans for everyone -- individuals and companies of all sizes. Since 1960, we`ve partnered with leading doctors, hospitals, employers and community organizations to enhance the lives of those we touch. We offer six distinct health insurance lines: • Group Insured Commercial • Individual • Medicare • Medicaid • Self-Funded • Network Leasing HAP also provides: • Award-winning wellness programs • Community outreach • Digital health tools • Disease management services • Personalized customer service
Cellanyx has developed proprietary live tumor cell phenotypic biomarker tests to improve cancer risk-stratification and allow informed clinical decision making. The Companys unique approach provides quantitative and actionable information based on analysis of thousands of live tumor cells. The Companys tests employ a microfluidic platform combined with machine vision and machine learning approaches to analyze phenotypic morphological, biochemical and biophysical markers. Cellanyx has demonstrated initial clinical proof-of-concept with its lead phenotypic test in prostate cancer. The initial clinical proof-of-concept study was conducted to demonstrate improved risk stratification in men with low and intermediate Gleason grade (6 and 7) disease and reduce the number of repeat biopsies. Furthermore, analysis of field samples (away from the suspicious core) demonstrated the potential value of Cellanyx phenotypic test as it was able to analyze the tumor microenvironment conditions and predict expected adverse pathology from samples that were not taken from the suspicious core. These new findings from the Cellanyx prostate test are transformative as it will reduce the errors in diagnosing cancers early due to sampling heterogeneity of prostate biopsies.